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Peripheral arterial occlusive disease (PAOD) of
the lower extremities has been attributed primarily
to atherosclerotic changes and the risk factors asso-
ciated with athersclerotic disease, including smok-
ing, male gender, hypercholesterolemia, and age.1,2
The prevalence of PAOD in the general population
increases with age.3,4 Some estimates indicate that
the prevalence of PAOD has an age adjusted rate of
12%.5,6
Intermittent claudication (IC) is the most com-
mon debilitating symptom of PAOD. In 1987, an
estimated 4,234,000 people in the United States
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had IC.3 Patients with IC are severely impaired in
their ability to perform daily activities.7 Confirma-
tion of impairment is reflected in lower quality-of-
life scores on physical functioning scales and disease-
specific scales measuring patients’ perception of
walking speed and distance.8,9
Established medical therapies available for IC
include exercise programs, risk factor modifications,
and surgical and endovascular procedures.10 How-
ever, many of these are not applicable for many
patients with IC.11 Pharmacologic therapy for IC in
the United States is limited to a single agent whose
usefulness has been questioned.12 Numerous drugs
have been studied or are in development for the
treatment of IC, including prostaglandins and
prostaglandin analogs, vasodilating agents, calcium
channel blockers, hemorrheologic agents, anticoag-
ulants, and antiplatelet agents.13
Cilostazol has significantly more potent vasodila-
tory and antiplatelet activity than aspirin.14 In addi-
tion, cilostazol has antiproliferative properties and
enhances the effects of prostacyclin, the endogenous
vessel-wall antiplatelet, and vasodilating substance.15
This study tested the hypothesis that treatment
with cilostazol (100 mg b.i.d. for 16 weeks) would
increase walking distances in patients with IC.
METHODS
Two hundred thirty-nine patients with IC caused
by lower extremity PAOD were evaluated in a 16-
week, multicenter, randomized, double-blind, placebo-
controlled, parallel-design study.
Study design. Patients were required to sign an
informed consent form before undergoing screening
procedures, beginning with a medical history and
physical examination. The screening period lasted 2
weeks. After randomization to double-blind study
medication, visits occurred at weeks 2, 4, 8, 12, and
16. At each visit the following safety assessments
were made: serum chemistry, hematology, electro-
cardiogram, vital signs, concomitant medication
changes, and adverse events.
Treadmill testing was performed at the two
screening visits and at postrandomization weeks 8,
12, and 16. At baseline, week 8, and week 16, two
treadmill tests were performed 3 to 4 hours apart. At
weeks 8 and 16, study medication was administered
immediately after the first treadmill tests.
At the completion of 16 weeks, another physical
examination assessed potential changes, and both
the physicians and the patients evaluated the effect
of the study drug on claudication symptoms. In
addition, at weeks 8 and 16, two functional status
questionnaires, the Medical Outcome Scales Health
Survey (SF-36) and the Walking Impairment Ques-
tionnaire (WIQ), were administered.
Inclusion criteria. Eligible patients were more
than 40 years of age and had had PAOD for at least
6 months with no change in symptoms in the previ-
ous 3 months. The presence of PAOD was verified
in patients by a Doppler-measured ankle-brachial
index (ABI) of  0.90 or lower after 10 minutes of
rest and by a reduction in the blood pressure of at
least one ankle artery by a minimum of 10 mm Hg
when measured 1 minute after claudication-limiting
treadmill testing. If these criteria were not met, a
decrease of at least one ankle artery blood pressure
by a minimum of 20 mm Hg when measured 1
minute after treadmill testing was accepted for entry
into the study. Eligible patients had a baseline initial
claudication distance (ICD) of at least 54 meters
(corresponding to 1 minute on the treadmill), a
reproducible absolute claudication distance (ACD;
variance no greater than 20% between the two
screening visits), and a maximum allowable ACD of
805 meters (corresponding to 15 minutes).
Patients were excluded for the following reasons:
limb-threatening PAOD, including gangrene or
ischemic rest pain; surgical or endovascular proce-
dures in the preceding 3 months; gross obesity;
hypertension, >200 systolic or >100 diastolic (mm
Hg); current malignancy (except basal cell carcino-
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Table I. Patient demographic characteristics
Cilostazol (100 mg b.i.d.) Placebo
Parameter Mean Percent Mean Percent
Age (yr)
Mean ± SD 64.8 ± 9.4 64.5 ± 8.8
Range 45 to 91 41 to 88
Gender 
Male 90 75.6 90 75.0
Female 29 24.4 30 25.0
Race 
White 106 89.1 102 85.0
Black 10 8.4 11 9.2
Hispanic 2 1.7 7 5.8
Asian 1 0.8 0 0.0
Weight (kg)
Mean ± SD 82.5 ± 16.6 79.6 ± 14.9
Range 42 to 130 49 to 127
Diabetes 
Yes 30 25.2 37 30.8
No 89 74.8 83 69.2
Cigarettes 
Never 18 15.1 9 7.5
Previous 58 48.7 63 52.5
Current 43 36.1 48 40.0
ma or in situ carcinoma); Buerger’s disease or deep
venous thrombosis in the previous 3 months; inabil-
ity to complete treadmill testing for reasons unrelat-
ed to IC; or bleeding problems. Drugs with signifi-
cant effects on peripheral vessels, bleeding, hemosta-
sis, or platelet function were prohibited during the
study. Among these were warfarin, heparin, and pen-
toxifylline. Antiplatelet agents, such as aspirin, per-
santine, and ticlopidine, and nonsteroidal antiin-
flammatory agents were also prohibited.
The patients were not given specific risk factor
modification instructions about smoking cessation,
lipid intake limitation, or exercise. All patients were
free to follow any other medical care regimens.
Treadmill design. Testing was conducted with
a variable-grade, constant-speed treadmill. This
treadmill design begins at a 0% incline with a speed
of 3.2 km/hr (2 miles/hr), and the incline
increases by 3.5% every 3 minutes.
ABI. ABIs were calculated as the ratio of the low-
est pressure from either the right or left posterior or
anterior tibial (dorsalis pedis) arteries over the great-
est brachial systolic pressure. This calculation allowed
for patients’ entry into the study. For analysis pur-
poses, the highest pressure in each limb was used for
determination of an “affected limb” (limb with the
lower ABI at baseline), and the change in ABI was
then assessed with this method of calculation.
Functional status assessments. The SF-36 is a
general health questionnaire that measures the
patient’s perception of physical health, mental
health, and combined physical and mental health.
Four parameters (physical function, bodily pain,
role-physical, and general health perception) com-
pose the physical component scale. The WIQ assess-
es the patients’ impressions of walking speed and
distance and specific measures of walking difficulty
because of pain or other problems.
Statistical methods. The primary variable ana-
lyzed for efficacy was ACD, as measured by stan-
dardized treadmill testing. Additional efficacy out-
comes included ICD, ABI, and the functional status
questionnaires. All statistical tests performed were
two-sided. Values were significant if p was less than
or equal to 0.05. The baseline comparability
between the treatment group and the placebo group
was assessed by comparing means, standard devia-
tions, and proportions. Continuous efficacy mea-
sures were analyzed by variance or the Wilcoxon
rank sum test. The data for claudication distances
were analyzed in terms of logarithm ratios (walking
distance at postbaseline/walking distance at base-
line).16-18 This analysis expresses results as a percent
change from baseline and reduces the effects of
extreme values. In addition, results were expressed
as change from baseline in meters and as change in
seconds walked. Estimated treatment effects were
calculated with a ratio of the geometric means
(cilostazol/placebo) to provide an estimate of the
net drug effect. Subjective improvement of claudica-
tion, as assessed by the patient and the investigator
at the end of treatment, were analyzed using the
Cochran-Mantel-Haenszel test. In an attempt to use
all data obtained throughout the period of study
treatment rather than at selected time points, a
repeated measure of analysis of variance was applied
to walking distances, functional status question-
naires, and ABI results. For efficacy variables mea-
sured sequentially at time points, the following two
types of analyses were performed: (a) a last visit-
analysis and (b) a time-point-by-visit analysis.
RESULTS
This trial was performed at 17 centers in the
United States after receiving approval from the Insti-
tutional Review Boards. Analysis of baseline demo-
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Table II. Absolute claudication distance and time (last observation carried forward)
Cilostazol Placebo
Meters ± SE Total seconds ± SE Meters ± SE Total seconds ± SE
Baseline
Trough 236.9 ± 13.6 265.0 ± 15.2 244.3 ± 13.7 273.3 ± 15.3
Peak 211.4 ± 12.4 236.5 ± 13.8 219.3 ± 12.9 245.2 ± 14.5
Week 8
Trough 285.4 ± 16.8 319.2 ± 18.8 271.9 ± 17.2 254.5 ± 19.2
Peak 272.3 ± 15.5 304.6 ± 17.3 252.9 ± 17.0 282.9 ± 19.0
Week 12
Trough 313.4 ± 19.9 350.5 ± 22.3 279.2 ± 18.3                      257.0 ± 20.5
Week 16
Trough 332.6 ± 20.0 372.0 ± 22.4 281.1 ± 19.2                      255.0 ± 21.5
Peak 306.9 ± 19.1 343.3 ± 21.4 267.5 ± 18.5 299.3 ± 20.7
graphics showed no significant or clinically relevant
difference between the treatment groups (Table I).
Two hundred ninety-eight patients were screened
for inclusion in the trial. One hundred nineteen
patients randomly received cilostazol (6-[4-(1-cyclo-
hexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-
2(1H)-quinolinone)(Otsuka Pharmaceutical Com-
pany, Ltd., Tokushima, Japan) 100 mg b.i.d. One
hundred twenty patients received matching placebo
tablets. Randomized patients were primarily white
(87%) men (75.3%), with an average age of 64.6
years and a range of 41 to 91 years.
Approximately one half of the randomized
patients were previous cigarette smokers, and 38%
were current smokers. Therefore 88.6% of the
patients had a cigarette-smoking history (mean,
53.5 pack-years). The treatment groups had no
apparent differences with respect to smoking or
medical history. The most common medical histo-
ries were for previous myocardial infarction
(18.8%) and previous attempts at distal revascular-
ization (12.5%).
Trough and peak baseline ACD values were
236.9 and 211.4 meters, respectively, in the
cilostazol group and 244.3 and 219.3 meters in
the placebo group. No differences were noted in
baseline ABI scores of 0.64 ± 0.02 and 0.68 ±
0.02, cilostazol and placebo, respectively.
Two hundred twelve patients (88.7%) completed
the study, 104 in the cilostazol group and 108 in the
placebo group. Fifty-nine patients failed to qualify
for the study because of out-of-range treadmill test-
ing, use of prohibited medications, or inability to
return for follow-up visits. Patients included in the
intent-to-treat analysis of the treadmill data had at
least one postbaseline treadmill test. Intent-to-treat
analysis of the safety population included all patients
who ingested at least one dose of study medication.
Evaluation of efficacy. Cilostazol-treated
patients walked significantly farther trough ACD
distances than placebo-treated patients walked at
all time points in therapy (Table II). The mean
meter change from baseline after 16 weeks was
96.4 meters and 31.4 meters for the patients who
received cilostazol and placebo, respectively.
Improvement in trough ACD at week 8 was 49.1
meters for patients who received cilostazol versus
20.6 meters for patients who received placebo, and
at week 12, the meter improvement was 77.1 for
patients who received cilostazol compared with
29.5 for patients who received the placebo, at all
time points (p ≤ 0.0013; Fig.1).
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Table III. Estimated treatment effects
Treatment comparison Week 8 Week 12 Week 16
ICD ACD ICD ACD ICD ACD
Cilostazol vs placebo (trough)
Geometric mean 1.07 1.13* 1.15* 1.19* 1.20* 1.29*
Change (m) 13 27* 28* 46* 28* 62*
% Change 10 15* 19* 21* 27* 32*
Cilostazol vs placebo (peak)
Geometric mean 1.10 1.16* na na 1.20* 1.21*
Change (m) 12 29* na na 26* 48*
% Change 19* 22* na na 32* 27*
*p < 0.05.
Table IV. Perception of patients and investigators after 16 weeks of treatment
Cilostazol 100 mg b.i.d. Placebo
Patient* Investigator† Patient Investigator
n             (%) n (%) n (%) n (%)
Judgment
Much better 14 (11.8) 8 (6.7) 12 (10.0) 6 (5.0)
Better 52 (43.7) 48 (40.3) 30 (25.0) 33 (27.5)
Unchanged 44 (37.0) 54 (45.4) 64 (53.3) 72 (60.0)
Worse 5 (4.2) 3 (2.5) 8 (6.7) 4 (3.3)
Much worse 0 (0.0) 0 (0.0) 3 (2.5) 1 (0.8)
Unknown 4 (3.4) 6 (5.0) 3 (2.5) 4 (3.3)
*p = 0.0043. 
†p = 0.0408.
The primary end point was ACD (trough) at
week 16 versus baseline. The improvement for
patients on cilostazol resulted in an estimated
treatment effect of 1.29, a 29% improvement of
the cilostazol-treated patients over the placebo-
treated patients (p = 0.0001). The 95% confidence
interval was 1.17 to 1.41.
Supplemental analysis showed similar improve-
ment in the estimated treatment effects for trough
ACD at weeks 8 and 12 of 1.13 and 1.19, respective-
ly (p ≤ 0.001) (Table III). The improvement in ACD
in the cilostazol-treated patients over the placebo-
treated patients was also noted in the second (peak)
treadmill tests conducted at weeks 8 and 12, in which
the estimated treatment effects were 1.16 and 1.21,
respectively (p ≤ 0.0012). No significant differences
were noted between treadmill test 1 (trough) and
treadmill test 2 (peak) ACD values (Tables I and III).
The number of patients in the cilostazol-treated
group with an improvement in ACD greater than 50%
was approximately double the number in the placebo
group (p < 0.003).
All subgroups analyzed (age, smoking status, sex,
race, and presence of diabetes) performed better on
treadmill testing with cilostazol treatment. The small
subgroup size precluded the derivation of inferential
statistics.
Results similar to those for ACD were observed for
the ICD at all measured time points, with the excep-
tion of week 8, in which no significant difference was
noted between treatment groups (Table III).
The SF-36 physical component scale score
improved significantly in cilostazol-treated patients
after 16 weeks of therapy when compared with
placebo-treated patients. The physical component
scale score increased by 2.99 points in the cilostazol-
treated patients and by 0.12 points in the placebo-
treated patients (p = 0.0059). In evaluations of
patients’ perceptions of physical function at week
16, the cilostazol-treated group showed a mean pos-
itive change from baseline of 8.3 points versus 2.3
points in the placebo-treated group (p = 0.0024).
Compared with placebo, the cilostazol-treated
group also improved for the bodily pain (p =
0.0772), general health (p = 0.436), and role-physi-
cal (p = 0.061) parameters. No negative effects were
noted in the mental components of the SF-36 in
either treatment group.
In the WIQ, patients benefited from cilostazol
after 16 weeks of treatment. Walking speed, assessed
by this questionnaire, improved by 20% with cilosta-
zol and did not change in the placebo-treated group
(p = 0.0331). Specific measures of walking difficulty,
including “difficulty walking caused by pain or stiff-
ness in joints,” “difficulty walking caused by other
problems,” and “difficulty walking caused by pain or
aching in calves,” were improved in the cilostazol-
treated patients. No changes in the walking distance
score were noted.
Therapeutic assessment by both investigators
and patients favored treatment with cilostazol over
placebo (Table IV). In the cilostazol-treated
group, 55.5% of the patients felt “much better” or
“better” versus 35.0% of the patients in the place-
bo-treated group. The investigators felt that 47.0%
of the patients were “much better” or “better” in
the cilostazol-treated group as compared with
32.5% of the patients in the control group. Both
the investigators’ and patients’ judgments were
significant (p < 0.05).
Resting ABI increased from 0.64 ± 0.02 at base-
line to 0.70 ± 0.02 after 16 weeks of treatment, rep-
resenting a 9% increase. In the placebo group the
mean ABI was 0.68 ± 0.02 at baseline and increased
to 0.69 ± 0.02 at week 16 (p = 0.0125 cilostazol vs
placebo).
Evaluation of safety. Generally, cilostazol was
well tolerated. Patients in the cilostazol-treated
group had higher incidences of headaches (30.3%),
abnormal stools (16.0%) (generally described as
“loose stools”), diarrhea (12.6%), and dizziness
(12.6%) compared with the placebo group (9.2%,
5.0%, 6.7%, and 5.0%, respectively) (p < 0.05). Most
of the headaches reported were mild and responded
to nonprescription analgesic medication. Three
patients, two in the cilostazol-treated group and one
in the placebo-treated group, discontinued partici-
pation in this study because of headaches. No
patients discontinued the study because of abnormal
stools or diarrhea. One patient in the cilostazol-
treated group discontinued because of dizziness.
JOURNAL OF VASCULAR SURGERY
Volume 27, Number 2                                                                                                                                                      Money et al. 271
Fig. 1. Mean percent change from baseline ACD.  p <0.05.
Of the 27 patients (11.3%) who withdrew from
the study, 21 withdrew because of adverse events.
Total withdrawals and adverse-event withdrawals were
similar between the cilostazol-treated and the place-
bo-treated groups (15 versus 12, and 12 versus 10,
for cilostazol and placebo, respectively).
Similarly, the incidence of serious adverse events
was similar between the two treatment groups. The
incidence was 11.8% (13/119) in cilostazol-treated
patients and 9.2% (11/120) in placebo-treated
patients. A total of 12 patients, seven in the cilostazol-
treated group and five in the placebo-treated group,
discontinued participation in the study because of seri-
ous adverse events. One patient in the placebo-treated
group died while on study medication, and one patient
in the cilostazol-treated group died of a myocardial
infarction 6 days after stopping study medication.
No significant differences between groups were
noted in laboratory safety assessments, with the
exception of triglyceride and plasma HDL levels.
Mean triglyceride levels from baseline to end of
treatment decreased by 48.8 ± 10.8 mg/dl (mean ±
SE) in the cilostazol group and by 36.4 ± 20.0
mg/dl in the placebo group. In addition, mean
HDL cholesterol from baseline to end of treatment
increased from 47.6 ± 1.2 mg/dl to 52.8 ± 1.4
mg/dl (mean ± SE) in the cilostazol group and from
48.1 ± 1.1 mg/dl to 50.2 ± 1.2 mg/dl in the place-
bo group.
DISCUSSION
In this well-controlled, multicenter clinical trial,
cilostazol-treated patients significantly increased the
time to initial onset of symptoms, as well as their
maximal walking distances, functional status mea-
sures, and ABIs. Striking, reproducible changes were
observed in the end points of walking distances (ICD
and ACD) in patients treated with cilostazol for 16
weeks. In variable-grade, constant-speed treadmill
testing, the energy cost of walking is nonlinear
because, as the patient progresses to longer distances
(time) on the treadmill, the energy expenditure
increases significantly as the incline increases. The
walking changes and increased energy expenditure
were coupled with significant corroborative improve-
ments in functional status as noted in both the phys-
ical function scale and the physical component scale
composite score of the SF-36, in the walking speed
assessment of the WIQ, and in the judgments by
patients and investigators at the end of treatment.
The average patient had an increase in ACD values of
approximately one-third to one-half at the end of the
16-week trial. When patients given cilostazol were
asked to judge whether they had improved signifi-
cantly relative to pretreatment, approximately one
half of them felt they were “better” or “much better”
versus one third in the placebo group.
The most common side effect was headache. More
than one-quarter of the patients in the cilostazol-treat-
ed group had mild-to-moderate headaches. Four
patients reported severe headaches, and two patients
discontinued the study because of headaches. Most of
the headaches responded to nonprescription anal-
gesics. The second most common complaint was
abnormal stools, primarily loose stools.
This study represented a scientifically rigorous
examination of the effects of cilostazol on walking dis-
tances. All end points were defined a priori, and all
analyses were carried out according to protocol, by an
independent statistical group. Only one patient (on
placebo) was unblinded during the course of the trial.
The patient was unblinded to the investigator only
after an abnormally high alkaline phosphatase level was
detected. With careful monitoring according to Food
and Drug Administration guidelines, no biases were
noted.
Despite encouraging results from surgical and
endovascular modalities, the initial treatment of
claudication is usually a risk factor modification
program. Changes include the cessation of smok-
ing, dietary modification, and a routine exercise
program. Patterson et al.19 demonstrated that most
patients with IC improve significantly with a walk-
ing program. However, compliance with super-
vised exercise programs has been questioned
because of accessibility, cost, and patient dedica-
tion. An effective therapeutic agent for the amelio-
ration of the symptoms of IC would be a welcome
addition to clinicians’ limited array of effective
tools.
The action mechanisms of cilostazol are varied.
The main known pharmacologic effects include
antiplatelet, vasodilatory, and antithrombotic
activities.20 Additionally, cilostazol decreases tri-
glycerides and increases HDL levels.21 Smooth
muscle cell proliferation has been inhibited by
cilostazol in vitro.22 It can be hypothesized that
the mechanism by which cilostazol acts in claudi-
cation is multifactorial.
CONCLUSION
Cilostazol had a significant advantage over a
placebo in improving ACD, ICD, ABI, and func-
tional status measures. This trial showed statistically
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significant improvement in treadmill walking perfor-
mance after 16 weeks of therapy with cilostazol, 100
mg b.i.d. Cilostazol may represent a new option for
the treatment of mild-to-moderate IC in patients
with POAD.
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Dr. Robert B. Patterson (Providence, R.I.). Dr.
Money and his colleagues have presented data from a dou-
ble-blind, placebo-controlled, prospective trial investigat-
ing yet another candidate for the “holy grail” of pharma-
cologic management of IC. The choice of cilostazol,
which inhibits type II phosphodiesterase activity in
platelets, diminishes platelet aggregation, and acts secon-
darily as a vasodilator, has merit.
I have questions regarding the study design and the
significance of the findings.
First, why did the authors choose not to include a
placebo run-in period? A run-in period permits the initial
placebo effect to be established, and selects patients for
randomization who have stable claudication symptoms
and have no early rapid improvement through treadmill
training or placebo effect.
Second, why was ACD rather than ICD chosen as the
prime end point? The authors state that ICD is subjective,
and ACD is not. I disagree. ACD depends on the patient’s
motivation and tolerance of pain. ICD is more repro-
ducible and less prone to errors of population enthusiasm.
How do you account for the change in ABI, particu-
larly as no difference was found in treadmill walking
between peak and trough dosing? Most authors agree
there is no theoretic or experimental justification for the
use of vasodilators in claudication.
Was the positive effect on resting ABI consistent at all
19 centers? Did you measure postexercise recovery times?
Finally, could the authors share the absolute values for
the SF-36 scores and compare them with a nonclaudicant
elderly population with chronic disease? Claudicants have
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Pittsburgh, PA
Albert Yellin, MD
LAC & USC Medical Center
Los Angeles, CA 
DISCUSSION
worse responses to health questionnaires for a variety of
reasons, and further demonstration that these patients
match other claudicant populations may be useful.
Regarding the significance of the study, I am intrigued
that most studies demonstrating efficacy for drug therapy of
claudication have quite modest, although statistically signifi-
cant, improvements in treadmill walking. Literature of exer-
cise therapy alone, without institution of pharmacologic
agents, reports in excess of 100% improvement in treadmill
walking ability. Additionally, successful intervention
approaches with angioplasty or surgery also demonstrate
superior benefits of walking distance. Do the authors believe
that cilostazol, with its expense, need for chronic administra-
tion, and moderate degree of side effects, is clinically relevant
and not just statistically significant?
Rather than hailing cilostazol as the pentoxifylline of the
1990s, I suggest that efforts at pharmacologic management
of arterial claudication turn to investigations of new classes of
therapeutic agents, most notably those whose action mecha-
nisms target the metabolic efficiency of skeletal muscle
metabolism.
I enjoyed the presentation and encourage the authors to
continue to seek answers to a vexing problem that is one of
the more rapidly expanding clinical dilemmas facing our
health care system.
Dr. Samuel R. Money. Thank you, Dr. Patterson, for
your questions. You first asked why we did not include a
placebo run-in period. A pilot study performed before this
study demonstrated no real need for a placebo run-in. To
limit expense and extra time, we decided not to use a
placebo run-in period.
You next asked why ACD rather than ICD was chosen
as the prime end point. The type of treadmill testing done
determined the prime end point. The studies by Hiatt
found less variability with the type of treadmill we used,
with a constant speed and an increasing incline, and less
variability with ACD rather than ICDs.
Your third question asked how we accounted for the
change in ABI, and I really cannot tell you. The cilostazol
has many different effects. The change may be simply
caused by the platelet effect, or the vasodilating effect, or
the reduction in smooth muscle proliferation.
Were the positive effects in resting ABI consistent at
all 19 centers? No, they were not. In a multicenter study,
nothing is consistent at all 19 centers.
Finally, you asked us to share some values for the SF-
36 scores. For many patients, the values are well below
what was expected. As you stated, these patients are elder-
ly with chronic diseases, and, in general, they view their
health as poor. For vitality and physical scores, their SF-
36s, ranging from 0 to 100, averaged between 50 and 65.
This is lower than the general population in this age
group.
Finally, you asked whether the use of cilostazol, with its
expense, is justifiable. I cannot answer that question. More
extensive testing must be done, and time will define the use-
fulness of this drug.
Dr. John M. Porter (Portland, Ore.). This was a very
nice presentation. I do have several questions.
Dr. William Hiatt from Colorado, who pioneered the
use of the variable-load treadmill in claudication trials,
always reported the results in terms of time walked. You
have converted this to meters. I consider this a problem-
atic exercise, because the more the patients walk, the more
the incline increases, and the more metabolic energy is
required. So the walking at the end of the trial is not com-
parable with the walking at the beginning of the trial. I
believe the use of meters in your report is unique. I do not
believe anybody has ever used meters before. I would like
for you to justify the use of meters instead of time walked.
Also, you included patients who walked up to 875
meters. It is important to keep in mind that 875 meters is
18th-fairway claudication. Claudication trials should be
limited to 200 to 300 meters. Thank you.
Dr. Money. Dr. Porter, I appreciate your comments,
and I wholeheartedly expected more of you than just this, sir.
You first asked why we converted to meters rather
than time walked. As a vascular surgeon, I think in terms
of meters or distance walked. Your point that the longer
the patients walk, the harder the walk becomes makes the
results seem more striking because patients are walking
further and harder for a longer distance, which translates
to time. We used meters rather than feet, yards, or time for
the same reason.
The study was limited to a person who could walk for
15 minutes. You asked why we did not limit the walk to
200 to 300 meters. If you look at the average ICD and
ACD, they are well below this 800 level, with the average
patient having an ACD of 236 meters.
Dr. Wesley S. Moore (Los Angeles, Calif.). I enjoyed
your presentation. I would like to ask one question.
Your experimental group may have ended with a high-
er ABI because of a drug effect or because different pop-
ulation groups received the drug versus the placebo. Have
you considered a crossover study making the placebo
group the experimental group on a secondary trial and
vice versa? If those two groups are comparable, then the
new experimental group, that is, the old placebo group,
may benefit from a switch to the drug.
Dr. Money. Dr. Moore, I cannot explain why the ABI
was significantly increased. I agree with your point that a
crossover study would more clearly demonstrate this sta-
tistically. It would be a great study; however, the expense
incurred may not be worthwhile at this point.
JOURNAL OF VASCULAR SURGERY
Volume 27, Number 2                                                                                                                                                      Money et al. 275
BOUND VOLUMES AVAILABLE TO SUBSCRIBERS
Bound volumes of the Journal of Vascular Surgery for 1998 are available to subscribers only. They may
be purchased from the publisher at a cost of $108.00 for domestic, $134.82 for Canadian, and $126.00
for international subscribers for Vol. 27 (January to June) and Vol. 28 (July to December). Price includes
shipping charges. Each bound volume contains a subject and author index, and all advertising is removed.
Copies are shipped within 60 days after publication of the last issue in the volume. The binding is durable
buckram with the journal name, volume number, and year stamped in gold on the spine. Payment must
accompany all orders. Contact Subscription Services, Mosby, Inc., 11830 Westline Industrial Dr., St.
Louis, MO 63146-3318, USA. In the United States call toll free 800-325-4177, ext. 4351. In Missouri
or foreign countries call 314-453-4351.
Subscriptions must be in force to qualify. Bound volumes are not available in place of a regular Jour-
nal subscription.
